

Summary of risk management plan for Omekon (omega 3 fatty acid ethylesters)

This is a summary of the risk management plan (RMP) for Omekon 1000 mg capsule, soft. The RMP details important risks of Omekon, and how more information will be obtained about Omekon's risks and uncertainties (missing information).

Omekon's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Omekon should be used.

Important new concerns or changes to the current ones will be included in updates of Omekon's RMP.

I. The medicine and what it is used for

Omekon 1000 mg capsule, soft is authorised for hypertriglyceridaemia (see SmPC for the full indication). It contains omega 3 fatty acid ethylesters as the active substances and it is given by the oral route of administration.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Omekon, together with measures to minimise such risks and the proposed studies for learning more about Omekon's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Omekon is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Omekon are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Omekon. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Summary of safety concerns	
Important identified risks	Increase in bleeding time Elevated hepatic enzymes
Important potential risks	None
Missing information	Use during pregnancy and lactation Use in the paediatric population Use in patients with hepatic or renal impairment Use in elderly patients (> 70 years)

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Omekon.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Omekon.